Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
story of the week
Published in and
1 other channel

Journal Scan / Research · {not yet published}

Effect of Combined Use of SGLT2 Inhibitors and Pioglitazone on the Risk of MASH in Individuals With Type 2 Diabetes

Diabetes, Obesity & Metabolism

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

Diabetes, Obesity & Metabolism
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study
Diabetes Obes Metab 2024 Nov 05;[EPub Ahead of Print], CH Lee, DT Lui, LY Mak, CH Fong, KS Chan, JH Mak, CY Cheung, WS Chow, YC Woo, MF Yuen, WK Seto, KS Lam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.